www.fdanews.com/articles/175161-fda-approves-avanirs-acute-migraine-candidate
FDA Approves Avanir’s Acute Migraine Candidate
February 3, 2016
The FDA has granted approval to Avanir Pharmaceuticals’ Onzetra Xsail for the acute treatment of migraine with or without aura in adults.
A combination product, Onzetra Xsail delivers sumatriptan powder through the Xsail breath-powered delivery device. Sumatriptan previously has been approved by the FDA in tablet and injectable forms.